CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?

Murat Serilmez; Emre Özgür; Hilal Oğuz Soydinç; Ceren Tilgen Yasasever; Faruk Taş; Uğur Gezer; Hadiye Derya Duranyıldız

Makale detayları

CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?

Yazarlar:

Murat Serilmez | Emre Özgür | Hilal Oğuz Soydinç | Ceren Tilgen Yasasever | Faruk Taş | Uğur Gezer | Hadiye Derya Duranyıldız

Yayıncı:

Istanbul University

Ana Başlıklar:

Chest Diseases | Clinical Chemistry | Clinical Oncology

Dergi:

Journal of Advanced Research in Health Sciences Vol.8 Issue 1, pp.7-14

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001344265

pISSN:

2651-4060

Anahtar kelimeler:

Özet:

 Objective: Primary lung cancers that originate from epithelial cells are classified as carcinomas. Close monitoring of patients with predisposing conditions can enhance early diagnosis rates and facilitate the implementation of therapeutic approaches. LYVE-1 protein is localized to the lymphatic endothelial layer. This study aimed to evaluate the clinical utility of the serum protein and circulating mRNA of LYVE-1 in lung cancer. Materials and Methods: We performed ELISA and Real-time PCR to measure and compare the serum protein and circulating mRNA levels of LYVE-1 in the peripheral blood of 60 patients with advanced lung cancer and 20 controls. Results: Serum LYVE-1 protein and gene expression levels were significantly higher in patients with lung cancer than in controls p0.001. There was no association between LYVE-1 both protein and gene clinical parameters. The outcome of the ROC analysis, serum LYVE-1 protein AUC: 0.873 or LYVE-1 gene AUC: 0.921 in lung cancer patients. Conclusion: As far as we are aware, this study represents the first investigation to compare the protein and mRNA levels of LYVE-1 in the blood samples of lung cancer patients. Additional research involving a larger cohort of subjects will be necessary to gain a deeper understanding of the mechanisms and consequences of LYVE-1 inhibitors in lung cancer.

 Objective: Primary lung cancers that originate from epithelial cells are classified as carcinomas. Close monitoring of patients with predisposing conditions can enhance early diagnosis rates and facilitate the implementation of therapeutic approaches. LYVE-1 protein is localized to the lymphatic endothelial layer. This study aimed to evaluate the clinical utility of the serum protein and circulating mRNA of LYVE-1 in lung cancer. Materials and Methods: We performed ELISA and Real-time PCR to measure and compare the serum protein and circulating mRNA levels of LYVE-1 in the peripheral blood of 60 patients with advanced lung cancer and 20 controls. Results: Serum LYVE-1 protein and gene expression levels were significantly higher in patients with lung cancer than in controls p0.001. There was no association between LYVE-1 both protein and gene clinical parameters. The outcome of the ROC analysis, serum LYVE-1 protein AUC: 0.873 or LYVE-1 gene AUC: 0.921 in lung cancer patients. Conclusion: As far as we are aware, this study represents the first investigation to compare the protein and mRNA levels of LYVE-1 in the blood samples of lung cancer patients. Additional research involving a larger cohort of subjects will be necessary to gain a deeper understanding of the mechanisms and consequences of LYVE-1 inhibitors in lung cancer.

 Objective: Primary lung cancers that originate from epithelial cells are classified as carcinomas. Close monitoring of patients with predisposing conditions can enhance early diagnosis rates and facilitate the implementation of therapeutic approaches. LYVE-1 protein is localized to the lymphatic endothelial layer. This study aimed to evaluate the clinical utility of the serum protein and circulating mRNA of LYVE-1 in lung cancer. Materials and Methods: We performed ELISA and Real-time PCR to measure and compare the serum protein and circulating mRNA levels of LYVE-1 in the peripheral blood of 60 patients with advanced lung cancer and 20 controls. Results: Serum LYVE-1 protein and gene expression levels were significantly higher in patients with lung cancer than in controls p0.001. There was no association between LYVE-1 both protein and gene clinical parameters. The outcome of the ROC analysis, serum LYVE-1 protein AUC: 0.873 or LYVE-1 gene AUC: 0.921 in lung cancer patients. Conclusion: As far as we are aware, this study represents the first investigation to compare the protein and mRNA levels of LYVE-1 in the blood samples of lung cancer patients. Additional research involving a larger cohort of subjects will be necessary to gain a deeper understanding of the mechanisms and consequences of LYVE-1 inhibitors in lung cancer.

 Amaç: Primer akciğer kanserleri epitelyal hücrelerden türeyen karsinom lardır. Predispozan bozukluğu olan hastaların yakın takibi, erken tanı ve küratif tedavi yöntemlerinin oranlarında artış sağlayabilir. Hyaluronan için bir reseptör molekülü olan LYVE-1, lenfatik endotelde ifade edilir. Bu çalış ma, akciğer kanserinde LYVE-1in serum proteini ve dolaşımdaki mRNAsının klinik faydasını değerlendirmeyi amaçlamıştır. Gereç ve Yöntemler: İleri evre 60 akciğer kanseri hastası ve 20 sağlıklı kontrolün periferik kanında LYVE-1in serum protein ve dolaşımdaki mRNA seviyelerini ölçmek ve karşılaştırmak için ELISA ve Gerçek Zamanlı PCR uygulaması gerçekleştirildi. Bulgular: Akciğer kanserli hastalarda serum LYVE-1 protein ve gen ekspres yon düzeyleri kontrol grubuna göre anlamlı derecede yüksek bulunmuştur p0,001. Akciğer kanseri hastalarında serum LYVE-1 protein ve gen eks presyon düzeyleri ile klinik parametreler arasında bir ilişki bulunmamıştır. ROC analizine göre eğri altında kalan alanlar hesaplandığında; serum LYVE 1 proteini ve geni için AUC Area Under Curve değerleri sırasıyla 0,873, 0,921 şeklinde bulunmuştur. Sonuç: Bu çalışma, akciğer kanseri hastalarının kan örneklerinde LYVE-1in protein ve mRNA düzeylerini karşılaştıran ilk çalışmadır. Akciğer kanserin de LYVE-1 inhibitörlerinin mekanizmalarını ve sonuçlarını daha derinleme sine anlamak için daha geniş bir denek grubunu içeren ek araştırmalara ihtiyaç duyulmaktadır. Bu tür araştırmalar, bu alana ilişkin değerli bilgiler sağlamada faydalı olacaktır.

Makale detayları

CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?

Yazarlar:

Murat Serilmez | Emre Özgür | Hilal Oğuz Soydinç | Ceren Tilgen Yasasever | Faruk Taş | Uğur Gezer | Hadiye Derya Duranyıldız

Yayıncı:

Istanbul University

Ana Başlıklar:

Chest Diseases | Clinical Chemistry | Clinical Oncology

Dergi:

Journal of Advanced Research in Health Sciences Vol.8 Issue 1, pp.7-14

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001344265

pISSN:

2651-4060

LYVE-1

lung cancer

lymphatic biomarkerYVE-1

akciğer kanseri

lenfatik biyomarker

Sayı

Makale detayları

CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?

Yazarlar: Murat Serilmez | Emre Özgür | Hilal Oğuz Soydinç | Ceren Tilgen Yasasever | Faruk Taş | Uğur Gezer | Hadiye Derya Duranyıldız

Yayıncı: Istanbul University

Ana Başlıklar: Chest Diseases | Clinical Chemistry | Clinical Oncology

Dergi: Journal of Advanced Research in Health Sciences Vol.8 Issue 1, pp.7-14

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001344265

pISSN: 2651-4060

LYVE-1

lung cancer

lymphatic biomarkerYVE-1

akciğer kanseri

lenfatik biyomarker

Sayı

Yazarlar:

Murat Serilmez | Emre Özgür | Hilal Oğuz Soydinç | Ceren Tilgen Yasasever | Faruk Taş | Uğur Gezer | Hadiye Derya Duranyıldız

Yayıncı:

Istanbul University

Ana Başlıklar:

Chest Diseases | Clinical Chemistry | Clinical Oncology

Dergi:

Journal of Advanced Research in Health Sciences Vol.8 Issue 1, pp.7-14

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001344265

pISSN:

2651-4060